Pomykala KL, Hadaschik BA, Sartor O, et al. Next generation radiotheranostics promoting precision medicine. Ann Oncol. 2023;34(6):507–19. https://doi.org/10.1016/j.annonc.2023.03.001.

Article  CAS  PubMed  Google Scholar 

Cives M, Strosberg J. Radionuclide therapy for neuroendocrine tumors. Curr Oncol Rep. 2017;19(2):9. https://doi.org/10.1007/s11912-017-0567-8.

Article  CAS  PubMed  Google Scholar 

Waldmann CM, Stuparu AD, van Dam RM, Slavik R. The search for an alternative to [68Ga]Ga-DOTA-TATE in neuroendocrine tumor theranostics: current state of 18F-labeled somatostatin analog development. Theranostics. 2019;9(5):1336–1347. https://www.thno.org/v09p1336.htm.

Harris PE, Zhernosekov K. The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next? Front Endocrinol (Lausanne). 2022;31(13): 941832. https://doi.org/10.3389/fendo.2022.941832.

Article  Google Scholar 

Sundlöv A, Sjögreen-Gleisner K, Svensson J, et al. Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. Eur J Nucl Med Mol Imaging. 2017;44(9):1480–9. https://doi.org/10.1007/s00259-017-3678-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goetz TI, Lang EW, Prante O, et al. Three-dimensional Monte Carlo-based voxel-wise tumor dosimetry in patients with neuroendocrine tumors who underwent 177Lu-DOTATOC therapy. Ann Nucl Med. 2020;34(4):244–53. https://doi.org/10.1007/s12149-020-01440-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garin E, Tselikas L, Guiu B, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(1):17–29. https://doi.org/10.1016/S2468-1253(20)30290-9.

Article  PubMed  Google Scholar 

Sjögreen Gleisner K, Chouin N, Gabina PM, et al. EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. Eur J Nucl Med Mol Imaging. 2022;49(6):1778–809. https://doi.org/10.1007/s00259-022-05727-7.

Article  PubMed  PubMed Central  Google Scholar 

Uribe C, Peterson A, Van B, et al. An international study of factors affecting variability of dosimetry calculations, part 1: design and early results of the SNMMI dosimetry challenge. J Nucl Med. 2021;62(Suppl 3):36S-47S. https://doi.org/10.2967/jnumed.121.262748.

Article  CAS  PubMed  Google Scholar 

Brosch-Lenz J, Ke S, Wang H, et al. An international study of factors affecting variability of dosimetry calculations, part 2: overall variabilities in absorbed dose. J Nucl Med. 2023;64(7):1109–16. https://doi.org/10.2967/jnumed.122.265094.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Willowson KP, Ryu H, Jackson P, Singh A, Eslick E, Bailey DL. A comparison of 2D and 3D kidney absorbed dose measures in patients receiving 177Lu-DOTATATE. Asia Ocean J Nucl Med Biol. 2018;6(2):113–19. https://doi.org/10.22038/aojnmb.2018.26105.1182.

Ljungberg M, Celler A, Konijnenberg MW, et al. MIRD pamphlet No. 26: joint EANM/MIRD guidelines for quantitative 177Lu SPECT applied for dosimetry of radiopharmaceutical therapy. J Nucl Med. 2016;57(1):151–62. https://doi.org/10.2967/jnumed.115.159012.

Miyaji N, Yamashita K, Yoneyama H, et al. The questionnaire survey of japanese practice and environment for targeted radionuclide therapy in 2021. Nihon Hoshasen Gijutsu Gakkai Zasshi. 2023;79(3):262–270. https://doi.org/10.6009/jjrt.2023-1317.

Ukon N, Zhao S, Washiyama K, et al. Human dosimetry of free 211At and meta-[211At]astatobenzylguanidine (211At-MABG) estimated using preclinical biodistribution from normal mice. EJNMMI Phys. 2020;7(1):58. https://doi.org/10.1186/s40658-020-00326-7.

Article  PubMed  PubMed Central  Google Scholar 

Brosch-Lenz J, Kurkowska S, Frey E, Dewaraja YK, Sunderland J, Uribe C. An international study of factors affecting variability of dosimetry calculations, part 3: contribution from calculating absorbed dose from time-integrated activity. J Nucl Med. 2024;65(8):1166–72. https://doi.org/10.2967/jnumed.123.267293.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Siegel JA, Thomas SR, Stubbs JB, et al. MIRD pamphlet No. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999;40(2):37–61.

Google Scholar 

Garkavij M, Nickel M, Sjögreen-Gleisner K, et al. 177Lu-[DOTA0, Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy. Cancer. 2010;116(4 Suppl):1084–92. https://doi.org/10.1002/cncr.24796.

Article  CAS  PubMed  Google Scholar 

Kupitz D, Wetz C, Wissel H, et al. Software-assisted dosimetry in peptide receptor radionuclide therapy with 177Lutetium-DOTATATE for various imaging scenarios. PLoS ONE. 2017;12(11): e0187570. https://doi.org/10.1371/journal.pone.0187570.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carter LM, Ocampo Ramos JC, Kesner AL. Personalized dosimetry of 177Lu-DOTATATE: a comparison of organ- and voxel-level approaches using open-access images. Biomed Phys Eng Express. 2021;7:5. https://doi.org/10.1088/2057-1976/ac1550.

Article  Google Scholar 

Hosono M, Ikebuchi H, Nakamura Y, et al. Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy. Ann Nucl Med. 2018;32(3):217–35. https://doi.org/10.1007/s12149-018-1230-7.

Article  CAS  PubMed  PubMed Central  Google Scholar